NEXT GENERATION CONDOM CONTRACEPTION TO TACKLE SEXUALLY TRANSMITTED DISEASES & UNINTENDED PREGNANCIES
RESEARCHER PROFILE (Filmed October 2023)
Dr Simon Cook,
Executive Director, Operations
Eudaemon Technologies
Sydney, Australia
Dr. Simon Cook, Co-Founder and Executive Director of Operations at Eudaemon Technologies, has had a diverse and impactful career journey. Beginning with a background in biotechnology from the University of Wollongong, his focus on bacterial pathogenesis during his PhD led him to study Group A Strep and the streptokinase protein.
Subsequently, Dr. Cook ventured into a unique project funded by the Bill and Melinda Gates Foundation, where he became involved in the development of a next-generation condom to address existing issues such as feel, odour, and taste.
Motivated by the potential for significant social impact, Dr. Cook is dedicated to overcoming challenges and driving positive change in global health through his work at Eudaemon Technologies.
The innovative approach at Eudaemon Technologies involves replacing latex with tough hydrogel materials, offering a more skin-like feel with no odour, taste, or allergic reactions. Additionally, these materials have the potential to integrate small molecule drugs, presenting opportunities for enhanced user experience and additional protective measures against STIs.
Beyond his professional endeavours, Dr. Cook enjoys music, particularly playing the guitar, bass guitar, and drums. He also maintains an active lifestyle through sports including soccer and squash.
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Touched by bowel cancer and chasing science outcomes
Dr Josephine Wright is a Senior Research Fellow in the Gut Cancer group. She has been developing a translational network of labs, hospitals and clinics to enable validation of new approaches to prevent and treat colorectal and gastric cancer. Her key focus is studying human tumour organoids to better personalise therapy in cancer.
-
Biopsychosocial approaches to obsessive-compulsive, body image and eating disorders
Dr Nicola Acevedo is a Neuroscientist and Research Fellow with extensive expertise in developing novel therapeutics for neurological and psychiatric disorders, contributing to more than ten clinical trials. She specialises in brain stimulation and psychedelic treatments for obsessive-compulsive disorder (OCD) and related conditions, with a strong commitment to advancing personalised, evidence-based neurobiological therapies for severe psychiatric illness. Her approach integrates biopsychosocial and person-centred principles to improve treatment access and mental health outcomes.
